OPRM1 Polyclonal Antibody

Catalog No: #30874

Package Size: #30874-1 50ul #30874-2 100ul



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com


Description

| Product Name | OPRM1 Polyclonal Antibody |
|-----------------------|---|
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Purification | Affinity purification |
| Applications | WB |
| Species Reactivity | Ms,Rt |
| Immunogen Description | A synthetic synthetic peptide of human OPRM1 (NP_000905.3). |
| Other Names | OPRM1; LMOR; M-OR-1; MOP; MOR; MOR1; OPRM; opioid receptor mu 1 |
| Accession No. | Swiss-Prot#:P35372NCBI Gene ID:4988 |
| Calculated MW | 72kDa |
| Formulation | Avoid freeze / thaw cycles. Buffer: PBS with 50% glycerol, pH7.4. |
| Storage | Store at -20°C |

Application Details

WB 1:500 - 1:1000

Images



Western blot analysis of extracts of various cell lines, using OPRM1 antibody.

Background

This gene encodes one of at least three opioid receptors in humans; the mu opioid receptor (MOR). The MOR is the principal target of endogenous opioid peptides and opioid analgesic agents such as beta-endorphin and enkephalins. The MOR also has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol via its modulation of the dopamine system. The NM_001008503.2:c.118A>G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity but evidence for it having a causal role is conflicting. Multiple transcript variants encoding different isoforms have been found for this gene. Though the canonical MOR belongs to the superfamily of 7-transmembrane-spanning G-protein-coupled receptors some isoforms of this gene have only 6 transmembrane domains.

| Note: This product is for in vitro research use only and is not intended for use in humans or animals. | | | |
|--|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |